Quantum BioPharma Statistics
Share Statistics
Quantum BioPharma has -
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,965 |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 70.22K, so 2.42% of the outstanding
shares have been sold short.
| Short Interest | 70.22K |
| Short % of Shares Out | 2.42% |
| Short % of Float | 2.49% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.29 and the forward
PE ratio is -16.3.
Quantum BioPharma's PEG ratio is
0.01.
| PE Ratio | -0.29 |
| Forward PE | -16.3 |
| PS Ratio | 0 |
| Forward PS | 3 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.61 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Quantum BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.8,
with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.8 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.12 |
| Interest Coverage | -339.16 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | 3.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -14.32% in the
last 52 weeks. The beta is 1.47, so Quantum BioPharma's
price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | -14.32% |
| 50-Day Moving Average | 8.6 |
| 200-Day Moving Average | 5.82 |
| Relative Strength Index (RSI) | 78.72 |
| Average Volume (20 Days) | 578,566 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.14M |
| Net Income | -14.2M |
| EBITDA | -13.69M |
| EBIT | -14.87M |
| Earnings Per Share (EPS) | -12.49 |
Full Income StatementBalance Sheet
The company has 6M in cash and 824.92K in
debt, giving a net cash position of 5.17M.
| Cash & Cash Equivalents | 6M |
| Total Debt | 824.92K |
| Net Cash | 5.17M |
| Retained Earnings | -172.11M |
| Total Assets | 14.87M |
| Working Capital | -412.6K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -6.88M
and capital expenditures 1.43, giving a free cash flow of -6.88M.
| Operating Cash Flow | -6.88M |
| Capital Expenditures | 1.43 |
| Free Cash Flow | -6.88M |
| FCF Per Share | -6.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
